Scientists developing early Alzheimer’s disease detection sensor

By Melissa Shaw Researchers with the SFU Nanodevice Fabrication Group are developing a new biosensor that can be used to screen for Alzheimer’s disease and other diseases. An overview of their work has been recently published in the journal Nature Communications.

Their sensor works by detecting a particular type of small protein, in this case a cytokine known as Tumour Necrosis Factor alpha (TNF alpha), which is involved with inflammation in the body. Abnormal cytokine levels have been linked to a wide variety of diseases including Alzheimer’s disease, cancers, heart disease, autoimmune and cardiovascular disease.

TNF alpha can act as a biomarker, a measurable characteristic indicating health status.

COVID-19 can also cause inflammatory reactions known as -cytokine storms,- and studies have shown that cytokine inhibitors are an effective treatment for improving chances of survival.

-Our goal is to develop a sensor that’s less invasive, less expensive and simpler to use than existing methods,- says Engineering Science Assistant Professor Michael Adachi, the project’s co-lead.

-These sensors are also small and have potential to be placed in doctor’s offices to help diagnose different diseases, including Alzheimer’s disease.-

Adachi says that there are a number of established methods for detecting biomarker proteins such as enzyme-linked immunosorbent assay (ELISA) and mass spectrometry, but they have several drawbacks. These existing methods are expensive, samples need to be sent away to a lab for testing and it can take a day or more to receive the results.

He notes that their biosensor is extremely sensitive and can detect TNF alpha in very low concentrations (10 fM) - well below the concentrations normally found in healthy blood samples (200’300 fM).

Current screening tests for Alzheimer’s disease include a questionnaire to determine if the person has symptoms, brain imaging, or a spinal tap process which involves testing for the biomarker proteins in the cerebral spinal fluid of the potential patient.

The team has completed the proof-of-concept stage, proving that the two-electrode diode sensor is effective in detecting TNF alpha in a laboratory setting. They plan to test the biosensor in clinical trials to ensure it would be able to effectively detect biomarker proteins within a blood sample containing many different interfering proteins and other substances.

-We will continue testing the device’s ability to detect the same proteins using body fluid like blood samples,- says engineering science PhD candidate Hamidreza Ghanbari. -The other objective is to use the same device but a different receptor to detect proteins that are more specific to Alzheimer’s disease.-

The researchers have also filed a provisional patent application with the Technology Licensing Office (TLO) at SFU. The project takes an interdisciplinary approach combining leadership from Adachi in Engineering Science and professors Karen Kavanagh in the Dept. of Physics and Miriam Rosin in Biomedical Physiology and Kinesiology (BPK).

-We need to be sure each sensor is made exactly the same to the tolerance required for the concentration we are trying to predict or detect, and that’s the real challenge,- says Kavanagh.